Antisense oligonucleotide Targeting IGF-1R in a paclitaxelresistant prostate cancer model
| Project/Area Number |
22890113
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
FURUKAWA Junya Kobe University, 医学部・附属病院, 助教 (20448179)
|
|---|
| Project Period (FY) |
2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥1,599,000 (Direct Cost: ¥1,230,000、Indirect Cost: ¥369,000)
Fiscal Year 2010: ¥1,599,000 (Direct Cost: ¥1,230,000、Indirect Cost: ¥369,000)
|
|---|
| Keywords | 前立腺癌 / IGF-1R / 標的治療 / アンチセンスオリゴs |
|---|
| Research Abstract |
We establish paclitaxel-resistant PCa cells (PtxR PC3) and assess the anti-cancer activity of antisense oligonucleotide (ASO) targeting human IGF-IR in vitro and in vivo. We observed dose- and sequence-specific suppression of IGF-IR expression in IGF-1R ASO -treated PtxR PC3 cells in vitro which correlated with decreased proliferation and increased apoptosis. Combination of IGF-1R ASO with paclitaxel showed the drug interactions resulted in synergy in vitro. IGF-1R ASO suppressed PtxR PC3 tumor growth as a combination therapy with paclitaxel in vivo. In conclusion, IGF-IR ASO suppresses growth of PtxR PC3 tumors, synergistically enhancing paclitaxel sensitivity.
|
Report
(2 results)
Research Products
(3 results)
